INTRODUCTION
The clinical effect of a pretransplant positive T-lymphocytotoxic crossmatch (TLC) in the prediction of liver transplantation (LT) outcome is controversial [1] . LT is often performed before the results of crossmatch testing between the donor and recipient can be obtained. In many cases, a pretransplant positive TLC between a recipient thesurgery.or.kr and donor is shown subsequent to LT because of time constraints. Nevertheless, hyperacute rejection rarely occurs in patients with a pretransplant positive TLC [2] .
There are several studies of clinical outcomes in patients with positive crossmatch grafts. Some studies have reported that the presence of pretransplant lymphocytotoxic antidonor antibodies is not a prognostic factor in deceased donor liver transplantation (DDLT) [3, 4] . However, more recent studies have contradicted these findings, showing higher acute or chronic rejection rates and worsening graft survival in patients who have a positive TLC [5] [6] [7] [8] [9] [10] . The detrimental effects of a pretransplant positive TLC on patient and graft survival have also been emphasized in other studies of DDLT [1, 2, 6, [11] [12] [13] [14] [15] .
Recently, adult living donor liver transplantation (LDLT) has been widely performed because of the shortage of de- 
METHODS

Donors and recipients
LT was performed on a total of 230 patients at the National Cancer Center, Korea, between January 2005 and June 2010. Of these patients, 11 were excluded from this study due to DDLT. The remaining 219 patients were en- 
Acute cellular rejection
Acute cellular rejection (ACR) was defined as a biopsyproven episode [16] and was graded according to the Banff schema [17] . The indication for liver biopsy was a significant increase in the levels of total bilirubin, aspartate and alanine aminotransferase. The defining limit was 6 weeks [18] . An acute rejection episode was treated with bolus intravenous methylprednisolone, regardless of the severity at a starting dose of 20 mg/kg/day. The dose was reduced by half per day, and the therapy was continued for 5 days. Highdose methylprednisolone therapy was given 1 or 3 times.
There was no case of steroid resistant cellular rejection.
T-lymphocytotoxic crossmatch test
Complement-dependent-cytotoxicity and flow cytometry were performed preoperatively in all cases. The lymphocytotoxic crossmatch test was performed according to and negative (89.0%) TLC groups. In adult LDLT recipients at our institution, the rate of pretransplant positive TLC was 3.7% (8/219).
RESULTS
Results of pretransplant TLC among the recipients
Comparison of demographic and intraoperative data between the positive and negative TLC groups
The demographic and intraoperative data of both groups are shown in Table 1 thesurgery.or.kr Values are presented number (%). TLC, T-lymphocytotoxic crossmatch. Incidence of surgical complications after LDLT in the positive and negative TLC groups Table 2 shows the incidence of surgical complications after LDLT in each group. There was no significant difference between both groups in the incidence of hepatic artery thrombosis, hepatic vein stenosis and portal vein stenosis. Biliary tract complications, including biliary leakage and anastomotic stricture, were not significantly different between both groups. There was no significant difference between both groups in the incidence of reoperations.
Patient and graft survival rates between the positive and negative TLC group Fig. 1 shows LDLT patient survival rates at our center.
Based on the Kaplan-Meier analysis, 1-and 3-year patient survival rates were 85.7% and 85.7%, respectively, in the positive TLC group, while they were 94.6% and 85.6%, respectively, in the negative TLC group; the differences between both groups were not statistically significant (P = 0.68). One-and 3-year graft survival rates were 85.7% and 85.7%, respectively, in the positive group, and 93.9% and 83.7%, respectively, in the negative group (P = 0.73) (Fig. 2) . Table 3 shows the perioperative TLC findings and clinical outcomes of 8 patients. All 6 patients with a positive pretransplant TLC (2 patients were excluded because of refusal to receive the test after LT) had a negative TLC following LT without any treatment. The median time to a negative conversion of TLC was 1.5 weeks (range, 1 to 3 weeks).
Posttransplant TLC test results in patients with a positive pretransplant TLC
Three of 6 patients (50%) with a pretransplant positive TLC had a negative TLC in the first postoperative week. In the other 3 patients (cases 3, 7, and 8), titers of antidonor antibodies decreased as measured by the complement-dependent cytotoxicity test or the percentages of cell death de- [21] have demonstrated, in a study of pediatric LDLT, that the positivity rate of the pretransplant lymphocytotoxic crossmatch tests is higher in pediatric patients than in adult patients. They also mentioned that the reason for this discrepancy may be that most cases in their study had biliary atersia and received some blood transfusions prior to LT. This suggestion concurs with our study. Koneru et al. [22] have reported the effect of blood transfusion on the prognoses of liver recipients. They also stated that transfusion recipients have significantly higher panel reactive antibody levels (P ＜ 0.02). Even though this did not reach statistical significance, there was tendency toward higher incidence of a positive crossmatch result.
Judging from these facts, there may be a relationship between the presence of history of pretransplant blood transfusion and the positivity of TLC results.
Some authors have reported that a positive TLC before LDLT is closely related to a higher ACR [5, 20, 23] and lower graft or patient survival [5, 23, 24] . They recommend that a pretransplant positive crossmatch be regarded as a factor predicting lower liver allograft survival and be used as an indicator for the use of more aggressive and individualized immunosuppressive regimens [5, 19, 23, 25, 26] . However, some previous studies have demonstrated that a pretransplant positive TLC does not negatively affect graft or patient survival in LDLT and does not increase ACR in pediatric LDLT [21] . In our study, we confirmed that ACR and graft or patient survival did not increase in the positive TLC group compared to the negative group in adultto-adult LDLT.
There are several reports about the relationship between the pretransplant lymphocytotoxic crossmatch and patient or allograft survival in LDLT [5, 19, 20, 23, 24, 27, 28] .
Attention should be paid to the evaluation of the cause of mortality after solid organ transplantation. Infection or multiorgan failure is often described as the major cause of mortality in many studies, which should be considered comprehensively. In our opinion, when discussing the ef-thesurgery.or.kr Suh et al. [24] have shown that pretransplant positive TLC is an independent risk factor causing early death after adult-to-adult LDLT using small-for-size grafts. They stated that all 4 patients died of multiorgan failure after early acute rejection episodes. It was difficult to determine whether the causes of graft loss were truly related with the acute rejection episodes. They also mentioned that a smallfor-size graft is related to detrimental outcomes. Three of the 4 patients had nonimmunologic disorder complications , such as hepatic venous stenosis, bleeding and sigmoid volvulus in the early postoperative period. Surgical repair was required for the complications before liver failure developed. In our study, 4 of the 8 patients underwent LDLT using a small liver graft (graft recipient weight ratio ＜1%) (Table 3 ). There were no mortalities in the early postoperative period in all 4 patients. LDLT using smallfor-size graft can be safely performed on patients with a pretransplant positive TLC without considering any immunologic treatment.
It is well known that patients with higher MELD scores before LT can detrimentally affect early posttransplant stages. Nevertheless, although the positive TLC group had higher MELD scores, the overall survival or graft survival rate did not show any difference between the 2 groups. These results can strongly support our conclusion that pretransplant positive TLC does not affect clinical outcomes of LDLT.
In our study, we found that cross-reactivity of T-lymphocyte disappeared after LT within 3 weeks (range, 1 to 3 weeks) without any immunologic treatment. We cannot give a precise explanation for the rapid disappearance of cross-reactivity after LT. A plausible explanation may be that liver allografts have a great capacity for secretion of soluble class I histocompatibility antigen into circulation and absorption of antidonor antibodies by Kupffer's cells [11] .
All patients undergoing posttransplant TLC test (n = 6) lost cross-reactivity rapidly within 3 weeks. None had an ACR episode. Based on these findings, it is conceivable that ACR within 6 weeks might be not related to a pre- Previous studies of crossmatch in LT have used the ACR definition [9, 20, 21, 27, 28] . In our study, we adopted this definition. However, donor specific antibodies can attribute to antibody-mediated rejection by which acute humoral rejection is mainly associated. Unfortunately, we did not perform C4d staining in all biopsy samples. Therefore, we could not provide the real incidence of acute humoral rejection. This is a limitation of this study.
In conclusion, this study demonstrates that, in LDLT, pretransplant TLC results may not be related to the posttransplant incidence of surgical complications and rejection episodes or graft and patient survival. Therefore, pretransplant TLC may not be useful for donor selection.
Some aggressive and tailored immunosuppressive regimens should not be considered in patients with a pretransplant positive TLC after LDLT. In addition, this study demonstrates that cross-reactivity of T-lymphocyte disappeared after LT within 3 weeks (range, 1 to 3 weeks) without any immunologic treatment.
